Single dose of hydroxynidone for kidney disease patients
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a single dose of the study drug hydroxynidone in people with different levels of kidney function, including healthy volunteers and those with kidney disease. The goal is to learn how the drug works in the body when kidneys are not working normally.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have either healthy kidneys (eGFR 90–129 mL/min) or mild, moderate, or severe kidney disease (eGFR 15–89 mL/min).
- You weigh at least 50 kg (men) or 45 kg (women), with a BMI between 18 and 28.
- You agree to stop smoking, alcohol, caffeine, and certain juices for 24 hours before and during the trial.
- You have not participated in another drug trial in the last 3 months.
- You do not have major health problems (other than kidney disease) that could affect safety, such as serious heart, liver, or stomach issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a single dose of an investigational medicine (NNC0537-1482) to see how it moves through the body in people with different levels of kidney function. It may help researchers understand how the drug is processed so it can be dosed safely in future studies.
This early-stage trial tests a new drug called ONO-3310 in two groups: healthy adults and people with kidney disease caused by type 2 diabetes. The study aims to understand how the drug works and whether it might help protect kidney function in people with diabetes.
This trial tests an investigational drug called HRS-1780 in people with chronic kidney disease. It aims to see if the drug can help slow kidney decline and is safe to use.
This trial tests whether a new drug, HTD1801, can protect or improve kidney function in people with type 2 diabetes and chronic kidney disease. It may help slow kidney damage and reduce protein in urine.
This trial tests a new medicine (CKD-339) in healthy people to see how the body processes it and if it is safe. It is an early-stage study that could help develop a treatment for conditions like high blood pressure or heart problems.
This study tests an investigational drug (RVX000222) to see if it helps people with kidney failure who are on dialysis. The drug is given in two parts and may help improve heart health, which is often a concern for dialysis patients.
Hear when a new Renal Insufficiency, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.